Encore Dermatology, Inc. Announces Phase 2 Safety Data Demonstrating Lower Systemic Drug Exposure With Impoyz™ (clobetasol propionate) Cream, 0.025%  Compared to Temovate® (clobetasol propionate) Cream, 0.05%

Malvern, PA, November 27, 2018

Encore Dermatology, Inc. today announced the publication of a Phase 2, open-label study in SKIN The Journal of Cutaneous Medicine. Subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temovate® (clobetasol propionate) Cream, 0.05% (56.3 vs 152.5 pg/mL, P=0.014).

 

Encore Dermatology Inc. Announces the launch of IMPOYZTM (clobetasol propionate) Cream, 0.025%, a newly formulated high-potency topical corticosteroid

Malvern, PA, May 1, 2018

Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.

Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%

Malvern, PA, January 17, 2017

Encore Dermatology Inc., a privately held dermatology 
company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% 
in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the
 relief of the inflammatory and pruritic manifestations of corticosteroid-responsive 
dermatoses.

Encore Dermatology, Inc. Announces Launch of HylatopicPlus® Lotion

Malvern, PA, Oct. 13, 2016

Encore Dermatology, Inc., a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus® Lotion in a convenient 14 oz. bottle with pump dispenser.

Encore Dermatology, Inc., A New Specialty Dermatology Company

Malvern, PA, May 18, 2015

Encore Dermatology, Inc. announced today that it has begun to commercialize HylatopicPlus® and Tetrix®, two highly regarded and established U.S. topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates.

 

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save